ALKSAlkermes plc

$40.63+46% 1Y

$40.63

$27.1352 weeks$52.99

Is the price fair?

Watch

A demanding price: priced for +15% a year vs +4% a year delivered and at the top of its own P/E range.

2 to watch, 1 without data

What the price assumes~+15% a yearderived · Jun 30, 2026

Priced for ~15% a year FCF growth. The price demands more than its three-year revenue growth of 4% a year, priced for acceleration.

Vs its own P/E rangedearer than 92% of its own historyderived

Expensive vs its own history: P/E 106.9 vs a 14.9 median over 13 quarters (+616% vs median).

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Alkermes plc trades at 107× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.

107

Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · 5.43× the median: the market pays up for this one

Price / sales: 5.50
Price / sales · as of 2026-Q2
Free cash flow yield: 2.5%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
Growth the price implies: +15%
Growth the price implies · The price pays for +15% free cash flow growth a year for a decade; the business has delivered +12% a year over the last three.